Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00105508
Status:
COMPLETED
Last Update Posted:
2018-07-26
First Post:
2005-03-15
Brief Title:
Sarizotan HC1 in Patients With Parkinsons Disease Suffering From Treatment-associated Dyskinesia
Sponsor:
EMD Serono
Organization:
EMD Serono
Study Overview
Official Title:
A Double-blind Placebo-controlled Multicenter Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg bid in Patients With Parkinsons Disease Suffering From Treatment-associated Dyskinesia
Status:
COMPLETED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if Sarizotan HC1 1 mg bid taken twice a day is effective in the treatment of dyskinesia associated with dopaminergic treatment of Parkinsons disease PD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None